1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline characteristics and demographics
All Patients (n = 44)IV Tirofiban (n = 25)IA Tirofiban (n = 19)P Value
Age (mean) (yr)70 (SD, 14)65 (SD, 15)77 (SD, 9).003
Sex (male) (No. %)21 (47.7%)11 (44.0%)10 (52.6%).570
Risk factors (No. %)
 Former or current smoker9 (20.4%)4 (16.3%)5 (26.3%).250
 Hypertension30 (68.2%)14 (56.0%)16 (84.2%).047
 Diabetes mellitus14 (31.8%)4 (16.0%)10 (52.6%).010
 Dyslipidemia17 (38.6%)7 (28.9%)10 (52.6%).096
 Atrial fibrillation5 (11.4%)1 (4.0%)4 (21.1%).077
 Ischemic heart disease8 (18.2%)3 (12.0%)5 (26.3%).223
 Active oncological disease0 (0%)0 (0%)0 (0%)NA
 Previous stroke3 (6.8%)1 (4.0%)2 (10.5%).395
Premorbid mRS (median, IQR)0 (0−1)0 (0–0)1 (0−2)<.001
Baseline NIHSS (median, IQR)12 (8−17)11 (7−18)15 (10−17).484
Occlusion level (No. %).041
 Intracranial ICA6 (13.6%)3 (12.0%)3 (15.8%)
 MCA M125 (56.8%)16 (50.0%)10 (52.6%)
 MCA M27 (15.9%)1 (4.0%)6 (31.6%)
 Intracranial VA1 (2.3%)1 (4.0%)0 (0%)
 Basilar artery5 (11.4%)5 (20.0%)0 (0%)
IV thrombolysis (No. %)14 (31.8%)9 (36.0%)5 (26.3%).495
Wake-up stroke (No. %)12 (27.3%)5 (20.0%)7 (36.8%).214
Onset to imaging (mean) (min)300 (SD, 266)253 (SD, 249)364 (SD, 284).175
Onset-to-groin time (mean) (min)411 (SD, 302)412 (SD, 318)410 (SD, 288).980
ASPECTS (median, IQR)9 (8−10)9 (8−9)9 (8−10).208
Symptomatic IAC (No. %)16 (36.4%)12 (48.0%)4 (21.1%).066
Stroke etiology (No. %).082
 Cardioembolic10 (22.7%)2 (8.0%)8 (42.1%)
 Atherothrombotic (ICAS-LVO)27 (61.4%)18 (72.0%)9 (47.4%)
 Undetermined3 (6.8%)2 (8.0%)1 (5.3%)
 Dissection2 (4.5%)2 (8.0%)0 (0%)
 Other2 (4.5%)1 (4.0%)1 (5.3%)
  • Note:—IAC indicates intracranial artery calcification; NA, not applicable; VA, vertebral artery.